• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Krevans Sarah was granted 6,082 shares, increasing direct ownership by 20% to 37,137 units (SEC Form 4)

    5/30/25 7:21:56 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Krevans Sarah

    (Last) (First) (Middle)
    C/O GRAIL, INC.
    1525 O'BRIEN DRIVE

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GRAIL, Inc. [ GRAL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/29/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/29/2025 A 6,082(1) A $41.1 37,137 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents an award of 6,082 restricted stock units ("RSUs") granted to Ms. Krevans under our 2024 Equity Incentive Plan. The RSUs will vest in full on the earlier to occur of (i) May 29, 2026 and (ii) the date of the next annual meeting of the Company's stockholders, in each case subject to continued service through the applicable vesting date. Each RSU represents the right to receive, at settlement, one share of common stock.
    Remarks:
    /s/Abram Barth, as Attorney-in-Fact for Sarah Krevans 05/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Leadership Updates

    Live Leadership Updates

    See more
    • GRAIL Appoints Sarah Krevans to Board of Directors

      MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

      10/21/24 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L was granted 6,082 shares, increasing direct ownership by 19% to 37,544 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/30/25 7:24:34 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Director Chase William J was granted 6,082 shares, increasing direct ownership by 20% to 35,782 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/30/25 7:23:43 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Director Mizell Steven was granted 6,082 shares, increasing direct ownership by 21% to 35,685 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/30/25 7:22:57 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GRAIL with a new price target

      Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

      4/21/25 8:38:45 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Morgan Stanley initiated coverage on GRAIL with a new price target

      Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

      11/27/24 7:29:05 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on GRAIL

      Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

      11/15/24 7:46:11 AM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    SEC Filings

    See more
    • GRAIL Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GRAIL, Inc. (0001699031) (Filer)

      5/30/25 5:05:21 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - GRAIL, Inc. (0001699031) (Filer)

      5/16/25 4:05:53 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by GRAIL Inc.

      S-8 - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:21:27 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      MENLO PARK, Calif., May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

      5/30/25 4:05:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL to Present at Jefferies Global Healthcare Conference 2025

      MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to

      5/21/25 4:05:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Financials

    Live finance-specific insights

    See more
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL to Announce First Quarter 2025 Financial Results

      MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves

      4/29/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results

      Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business

      2/20/25 4:02:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      10/10/24 7:45:32 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/14/24 3:35:14 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/12/24 4:47:47 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

      SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

      9/30/24 6:42:39 PM ET
      $GRAL
      Medical Specialities
      Health Care